Stock-Based Compensation

3 Months Ended

Mar. 31, 2022

Share-based Payment Arrangement [Abstract]

Our Compensation Committee of our Board of Directors granted 385,688 stock options and 489,252 restricted stock units ("RSUs"), and our electing non-employee directors received 25,682 deferred share units ("DSUs") during the three months ended March 31, 2022 under our Omnibus Equity Incentive Plan. The weighted average exercise price per share and weighted average fair value per share of the stock options granted during the three months ended March 31, 2022 and 2021, was $10.08 and $5.55, respectively. We estimated the fair value of the stock options using the following assumptions in our Black-Scholes model:

Dividend yield

0.40%

Expected volatility

58.28%

Risk-free interest rate

1.93%

Expected term (in years)

6.5 years

We measure the fair value of grants of RSUs and DSUs based on the closing market price of a share of our common stock on the date of the grant. The weighted average fair value per share was $10.08 for RSUs and $9.63 for DSUs granted during the three months ended March 31, 2022.

In the three months ended March 31, 2022 and 2021, we recognized $0.5 million and $0.8 million, respectively, of stock-based compensation expense. The majority of the expense, $0.4 million and $0.7 million, respectively, was recorded in selling and administrative expense in the Condensed Consolidated Statement of Operations, with the remaining expense recorded in cost of sales.

As of March 31, 2022, the unrecognized compensation cost related to the unvested portion of all stock-based awards was approximately $7.4 million and is expected to be recognized over the remaining vesting period of the respective grants.